127,920 results match your criteria myelogenous leukemia

Combined Central Retinal Arterial and Venous Occlusions due to Leukemic Infiltration.

Retin Cases Brief Rep 2021 Sep 19. Epub 2021 Sep 19.

Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium Department of Pathology, Antwerp University Hospital, Edegem, Belgium Department of Radiology, Antwerp University Hospital, Edegem, Belgium Faculty of Health Sciences, University of Antwerp, Edegem, Belgium Name and address for correspondence: Vincent M. De La Porte, M.D. E-mail: Telephone: +32 3 821 4428, Address: Department of Ophthalmology, Antwerp University Hospital, 2650 Edegem, Belgium.

Purpose: To report combined central arterial and venous occlusions secondary to bilateral leukemic interfascicular optic nerve infiltration in a 56-year-old man. This was the sole presentation of a relapse in T/Myeloid mixed-phenotype acute leukemia after 5 months of remission.

Methods: Case report with clinical photography. Read More

View Article and Full-Text PDF
September 2021

Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis.

Cell Stem Cell 2021 Jul 12. Epub 2021 Jul 12.

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, ON, Canada. Electronic address:

Current treatments for acute myeloid leukemia (AML) are often ineffective in eliminating leukemic stem cells (LSCs), which perpetuate the disease. Here, we performed a metabolic drug screen to identify LSC-specific vulnerabilities and found that nicotinamide phosphoribosyltransferase (NAMPT) inhibitors selectively killed LSCs, while sparing normal hematopoietic stem and progenitor cells. Treatment with KPT-9274, a NAMPT inhibitor, suppressed the conversion of saturated fatty acids to monounsaturated fatty acids, a reaction catalyzed by the stearoyl-CoA desaturase (SCD) enzyme, resulting in apoptosis of AML cells. Read More

View Article and Full-Text PDF

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.

JCO Glob Oncol 2021 Jul;7:1187-1193

Fred Hutchinson Cancer Research Center, Seattle, WA.

Purpose: Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common mechanism of resistance is the acquisition of a point mutation in the BCR-ABL kinase domain. Few studies have reported African patients with CML in regard to such mutations. Read More

View Article and Full-Text PDF

Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

JAMA Netw Open 2021 Jul 1;4(7):e2120165. Epub 2021 Jul 1.

School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.

Importance: Although BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (BCR-ABL TKIs) can substantially improve the survival rate of chronic myeloid leukemia (CML), they are clinically accompanied by severe hepatotoxicity.

Objective: To compare the relative risk (RR) of hepatotoxicity of new-generation BCR-ABL TKIs with that of imatinib, and to provide an overall assessment of the clinical benefit.

Data Sources: PubMed, Embase, Cochrane library databases, and ClinicalTrials. Read More

View Article and Full-Text PDF

Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.

Blood 2021 Jul;138(3):234-245

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is not fully understood. We discovered that venetoclax directly activated T cells to increase their cytotoxicity against acute myeloid leukemia (AML) in vitro and in vivo. Read More

View Article and Full-Text PDF

Pattern And Prevalence of Liver Involvement in Pediatric Acute Lymphoblastic and Myeloid Leukemia at Diagnosis.

J Pediatr Gastroenterol Nutr 2021 Jul 20. Epub 2021 Jul 20.

Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden Department of Pediatrics, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden Department of Pediatrics, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden Department of Pediatrics, University of Helsinki, Helsinki, Finland.

Objectives: The prevalence and significance of liver involvement at diagnosis was studied in pediatric acute lymphoblastic (ALL) and myeloid leukemia (AML).

Methods: A population based cohort of 122 pre B-ALL, 22 T-ALL and 45 AML patients was formed from the Nordic Society of Pediatric Hematology and Oncology leukemia registries (years 2005 - 2017). Hepatomegaly, elevated ALT, high INR, hypoalbuminemia and conjugated hyperbilirubinemia at diagnosis were used as markers for liver involvement. Read More

View Article and Full-Text PDF

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.

Leuk Lymphoma 2021 Jul 22:1-11. Epub 2021 Jul 22.

Hematology and Hemotherapy Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51. Read More

View Article and Full-Text PDF

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.

Epigenomics 2021 Jul 22. Epub 2021 Jul 22.

Second Department of Internal Medicine & Research Unit Hematology Unit, University General Hospital Attikon, Rimini, 12462 Chaidari, Athens, Greece.

5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic syndromes. However, response and survival rates vary considerably, while indicated treatment duration remains undefined. For these reasons, factors determining response and survival are of major importance. Read More

View Article and Full-Text PDF

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.

Front Oncol 2021 5;11:693670. Epub 2021 Jul 5.

Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Extramedullary relapse of acute promyelocytic leukemia is a rare phenomenon and is associated with a poor prognosis, with the central nervous system being the most common site of relapse. The current treatments are still limited. Venetoclax, a selective inhibitor of BCL2, is a small molecule that can cross the blood-brain barrier and shows a potential efficacy in the treatment of chronic lymphocytic leukemia with central nervous system involvement. Read More

View Article and Full-Text PDF

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.

Oncoimmunology 2021 8;10(1):1945804. Epub 2021 Jul 8.

GEMoaB GmbH, Dresden, Germany.

Chimeric antigen receptor T cells (CAR-T) targeting CD19 have achieved significant success in patients with B cell malignancies. To date, implementation of CAR-T in other indications remains challenging due to the lack of truly tumor-specific antigens as well as control of CAR-T activity in patients. CD123 is highly expressed in acute myeloid leukemia (AML) blasts including leukemia-initiating cells making it an attractive immunotherapeutic target. Read More

View Article and Full-Text PDF

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.

Front Physiol 2021 5;12:675811. Epub 2021 Jul 5.

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Read More

View Article and Full-Text PDF

Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients - A Dual-Center Retrospective Cohort Study.

J Blood Med 2021 14;12:623-633. Epub 2021 Jul 14.

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Introduction: Leukostasis is a medical emergency with high mortality which often occurs in acute myeloid leukemia patients with hyperleukocytosis. One of the therapies that can be used for leukostasis in acute myeloid leukemia is leukapheresis. However, whether leukapheresis can provide better survival benefit when compared with patients not receiving leukapheresis is still unclear. Read More

View Article and Full-Text PDF

Nuclear NAD homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells.

Sci Adv 2021 Jul 21;7(30). Epub 2021 Jul 21.

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.

Metabolic dysregulation underlies malignant phenotypes attributed to cancer stem cells, such as unlimited proliferation and differentiation blockade. Here, we demonstrate that NAD metabolism enables acute myeloid leukemia (AML) to evade apoptosis, another hallmark of cancer stem cells. We integrated whole-genome CRISPR screening and pan-cancer genetic dependency mapping to identify and as AML dependencies governing NAD biosynthesis. Read More

View Article and Full-Text PDF

Avapritinib: an emerging new therapy for systemic mastocytosis.

Expert Rev Hematol 2021 Jul 21. Epub 2021 Jul 21.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating mutations, usually D816V. SM can be indolent (ISM), smoldering (SSM) and advanced (AdvSM), the latter characterized by organ damage resulting from infiltrating neoplastic mast cells. The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. Read More

View Article and Full-Text PDF

Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.

Mol Cell 2021 Jul 12. Epub 2021 Jul 12.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. Electronic address:

Mutant isocitrate dehydrogenase (IDH) 1 and 2 play a pathogenic role in cancers, including acute myeloid leukemia (AML), by producing oncometabolite 2-hydroxyglutarate (2-HG). We recently reported that tyrosine phosphorylation activates IDH1 R132H mutant in AML cells. Here, we show that mutant IDH2 (mIDH2) R140Q commonly has K413 acetylation, which negatively regulates mIDH2 activity in human AML cells by attenuating dimerization and blocking binding of substrate (α-ketoglutarate) and cofactor (NADPH). Read More

View Article and Full-Text PDF

Posttransplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes.

Eur J Haematol 2021 Jul 20. Epub 2021 Jul 20.

Astellas Pharma, Inc, Northbrook, IL, USA.

Objectives: Maintenance therapy is one strategy to prolong survival in patients with acute myeloid leukemia (AML) following hematopoietic stem cell transplantation (HSCT). We evaluated real-world treatment patterns and outcomes in patients with newly diagnosed FLT3-mutated AML receiving HSCT after complete remission with first-line chemotherapy.

Methods: A global, retrospective chart review to evaluate maintenance therapy and outcomes in patients with FLT3-mutated AML after HSCT. Read More

View Article and Full-Text PDF

Clinical Implications of SRSF2 Mutations in AML Patients undergoing Allogeneic Stem Cell Transplantation.

Am J Hematol 2021 Jul 21. Epub 2021 Jul 21.

Medical Clinic and Policlinic 1, Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.

SRSF2 mutations are frequently found in acute myeloid leukemia (AML) and mostly affect the P95 residue. Mutation in this splicing factor mediate abnormal splicing associated with exon skipping events, including EZH2 as a crucial target. While SRSF2 mutations are enriched in secondary AML and associated with worse outcomes following chemotherapy consolidation, very little is known about the associated biological and clinical implications in AML patients consolidated with allogeneic hematopoietic stemcell transplantation (HSCT). Read More

View Article and Full-Text PDF

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).

Blood 2021 Jul 21. Epub 2021 Jul 21.

Universitaetsklinikum Wuerzburg, Wuerzburg, Germany.

Acute myeloid leukemia (AML) is attractive for the development of CAR T-cell immunotherapy because AML blasts are susceptible to T-cell-mediated elimination. Here, we introduce sialic-acid-binding immunoglobulin-like lectin (Siglec)-6 as a novel target for CAR T-cells in AML. We designed a Siglec-6-specific CAR with a targeting-domain derived from a human monoclonal antibody JML‑1. Read More

View Article and Full-Text PDF

Survival prognostic factors in patients with acute myeloid leukemia using machine learning techniques.

PLoS One 2021 21;16(7):e0254976. Epub 2021 Jul 21.

Department of Biology, School of Sciences, Razi University, Kermanshah, Iran.

This paper identifies prognosis factors for survival in patients with acute myeloid leukemia (AML) using machine learning techniques. We have integrated machine learning with feature selection methods and have compared their performances to identify the most suitable factors in assessing the survival of AML patients. Here, six data mining algorithms including Decision Tree, Random Forrest, Logistic Regression, Naive Bayes, W-Bayes Net, and Gradient Boosted Tree (GBT) are employed for the detection model and implemented using the common data mining tool RapidMiner and open-source R package. Read More

View Article and Full-Text PDF

WT1 inhibits AML cell proliferation in a p53-dependent manner.

Cell Cycle 2021 Jul 21:1-9. Epub 2021 Jul 21.

Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.

WT1 has been reported to function as an oncogene and a tumor suppressor in acute myeloid leukemia (AML). The molecular mechanisms have not yet been fully elucidated. Here, we report that p53, served as a tumor suppressor, plays a critical role in regulating the function of WT1 in AML. Read More

View Article and Full-Text PDF

3-Pyrazolo[4,3-]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.

J Med Chem 2021 Jul 21. Epub 2021 Jul 21.

Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.

The 3-pyrazolo[4,3-]quinoline moiety has been recently shown to be a privileged kinase inhibitor core with potent activities against acute myeloid leukemia (AML) cell lines in vitro. Herein, various 3-pyrazolo[4,3-]quinoline-containing compounds were rapidly assembled via the Doebner-Povarov multicomponent reaction from the readily available 5-aminoindazole, ketones, and heteroaromatic aldehydes in good yields. The most active compounds potently inhibit the recombinant FLT3 kinase and its mutant forms with nanomolar IC values. Read More

View Article and Full-Text PDF

Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.

Int J Lab Hematol 2021 Jul;43 Suppl 1:86-95

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.

CEBPA-mutant acute myeloid leukemia (AML) encompasses clinically and biologically distinct subtypes of AML in both adults and children. CEBPA-mutant AML may occur with monoallelic (moCEBPA) or biallelic (biCEBPA) mutations, which can be somatic or germline, with each entity impacting prognosis in unique ways. BiCEBPA AML is broadly associated with a favorable prognosis, but differences in the type and location of CEBPA mutations as well as the presence of additional leukemogenic mutations can lead to heterogeneity in survival. Read More

View Article and Full-Text PDF

A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.

Int J Lab Hematol 2021 Jul;43 Suppl 1:78-81

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Philadelphia (BCR-ABL)-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN can transform into an accelerated or a blast phase, which is associated with poor response to standard therapy and low overall median survival. We present an interesting case of a patient with a history of PMF and progression and summarize the current studies on genetic features of myeloproliferative neoplasms in blast phase (MPN-BP) with an emphasis on PMF. Read More

View Article and Full-Text PDF

Evaluation of pretreatment telomere length as a prognostic marker in intermediate-risk acute myeloid leukemia.

Int J Lab Hematol 2021 Jul 21. Epub 2021 Jul 21.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Introduction: The current framework for risk stratification is still insufficient for highly heterogeneous intermediate-risk acute myeloid leukemia (IRC-AML), which lacks specific genomic abnormalities.

Methods: In order to incorporate novel biomarkers to refine current risk stratification strategies for patients with this subtype, we investigated pretreatment telomere length (TL), which is essential for maintaining genomic stability, in 204 adults with de novo AML (non-acute promyelocytic leukemia).

Results: We found that TL measured at diagnosis did not decrease with advancing age in 204 patients with AML (R  = 0. Read More

View Article and Full-Text PDF

A Case of Acute Eosinophilic Leukemia with a Novel 6 Mutation.

Case Rep Hematol 2021 3;2021:5574766. Epub 2021 Jul 3.

Division of Hematology/Oncology, University of Rochester Medical Center, James P. Wilmot Cancer Institute, Rochester, NY, USA.

Acute eosinophilic leukemia (AEL) is a rare form of acute myeloid leukemia (AML) that requires prompt exclusion of reactive etiologies of eosinophilia and identification of an underlying acute myeloid neoplasm. Myeloid neoplasms with prominent eosinophilia often have rearrangements in the platelet-derived growth factor receptor () or ( or are associated with core-binding factor AML. In this report, we describe a 35-year-old male presenting with chest discomfort and altered mental status, found to have marked leukocytosis with eosinophilic predominance and an elevated blast count. Read More

View Article and Full-Text PDF

Clinical Characteristics and Predictive Factors of Invasive Fungal Disease in Pediatric Oncology Patients with Febrile Neutropenia in a Country with Limited Resources.

Pediatric Health Med Ther 2021 12;12:335-345. Epub 2021 Jul 12.

Division of Hematology/Oncology, Department of Pediatrics, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.

Background: The most common complication among pediatric oncology patients is febrile neutropenia (FN). Invasive fungal disease (IFD) is suspected when fever persists >4-7 days after empirical antibiotics. Its clinical characteristics and predictive factors associated with IFD among pediatric oncology patients with FN were thus explored. Read More

View Article and Full-Text PDF

A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Leuk Lymphoma 2021 Jul 21:1-11. Epub 2021 Jul 21.

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Relapse is the most common cause of treatment failure following allogeneic blood or marrow transplantation (alloBMT) for AML or MDS. Post-transplant maintenance therapies may prevent relapse. We conducted a phase II trial combining azacitidine (AZA) with GM-CSF in non-relapsed, post-transplant patients with AML or MDS. Read More

View Article and Full-Text PDF

Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency.

Stem Cell Res 2021 Jun 27;55:102445. Epub 2021 Jun 27.

Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), 08908 L'Hospitalet del Llobregat, Spain; Fondazione Pisana per la Scienza ONLUS, Pisa, Italy. Electronic address:

Germline heterozygous GATA2 mutations underlie a complex disorder characterized by bone marrow failure, immunodeficiency and high risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our understanding about GATA2 deficiency is limited due to the lack of relevant disease models. Here we generated high quality human induced pluripotent stem cell (iPSC) lines carrying two of the most recurrent germline GATA2 mutations (R389W and R396Q) associated with MDS, using CRISPR/Cas9. Read More

View Article and Full-Text PDF

Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors.

J Endocrinol Invest 2021 Jul 20. Epub 2021 Jul 20.

Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, Monserrato, 09042, Cagliari, Italy.

Purpose: Thyroid alterations including de novo appearance of thyroid autoimmunity are adverse effects of tyrosine kinase inhibitors, used in solid and hematologic cancer therapy, but the relationship between thyroid alterations during this treatment and the outcome of chronic myeloid leukemia remains unclear. Aim of this study was to investigate whether the presence of thyroid alterations may affect the clinical outcome of chronic myeloid leukemia on tyrosine kinase inhibitors.

Methods: We evaluated thyroid function and autoimmunity in 69 chronic myeloid leukemia patients on long-term therapy looking at the association between thyroid abnormalities and disease molecular response. Read More

View Article and Full-Text PDF